作者
Amr F Barakat, Sandeep Jain, Ahmad Masri, Laith Alkukhun, Mourad Senussi, Ahmet Sezer, Yisi Wang, Floyd Thoma, Aditya Bhonsale, Samir Saba, Suresh Mulukutla
发表日期
2021/5/1
期刊
Clinical Electrophysiology
卷号
7
期号
5
页码范围
649-658
出版商
American College of Cardiology Foundation
简介
Objectives
This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs. warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories, including ≥40 and <18.5 kg/m2.
Background
Clinical trials have not systematically tested the fixed DOAC dosing in underweight and morbidly obese patients.
Methods
We retrospectively included consecutive patients with nonvalvular AF with CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke/transient ischemic attack/systemic thromboembolism, Vascular disease, Age 65-74, Sex) of ≥1 receiving OACs at our hospital system (2010–2018). Patients were categorized into groups 1 (underweight: BMI of <18.5 kg/m2), 2 (normal/overweight: BMI of 18.5 to <30 kg/m2), 3 (grade 1/2 obesity: BMI of 30 to <40 kg/m2), and 4 (grade 3 obesity: BMI of ≥40 kg/m2). We further classified patients by DOAC versus …
学术搜索中的文章
AF Barakat, S Jain, A Masri, L Alkukhun, M Senussi… - Clinical Electrophysiology, 2021